Pin52 Studies Reporting Costs Associated With Invasive Meningococcal Disease in Eu-27: Methodology and Outcomes

Abstract

ventilator-associated pneumonia, where there are available alternatives but a rising antimicrobial resistance leading to lower treatment responses. Methods: A costeffectiveness model in hospitalized adult population was conducted to assess potential clinical and economic benefits of ceftazidime/avibactam (CAZ-AVI), an extended-spectrum cephalosporin along with a novel non-b-lactam b-lactamase inhibitor, with the standard treatment for nosocomial pneumonia (including ventilator-associated pneumonia). Clinical cure rates were adjusted by resistance rates published by Mexican healthcare institutions in accordance to crescent resistance of aerobic gram-negative organisms (i.e. Klebsiella pneumoniae and Pseudomonas aeruginosa) to currently available anti-infectives. The analysis was from the institutional perspective and considered public sector resource use and costs. Deterministic and probabilistic sensitive analyses were conducted to evaluate robustness of clinical and economic outcomes. Results: CAZ-AVI offers an incremental clinical cure rate of 12.09% (73.83%-61.74%); furthermore, ceftazidime/avibactam has a lower cost per healed patient (CAZ-AVI: USD 32,409; meropenem: USD 37,652) when considering microbiological sensitivity test, where the patient continues the treatment only if the pathogen turns out to be sensitive to the medication. Conclusions: Ceftazidime/ avibactam is a cost-effective alternative in the treatment of nosocomial pneumonia, including ventilator-associated pneumonia, for Mexican public sector. Adequate usage of CAZ-AVI allows healthcare professionals to implement strategies as recommended by WHO in the Global Action Plan on Antimicrobial Resistance to propitiate the availability and correct use of antibiotics as the main containment measure in the face of wide antimicrobial resistance spread.